Trial Profile

Phase I Study of GDC-0084, a Brain-Penetrant PI3 Kinase/mTOR Inhibitor, in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas After Radiation Therapy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paxalisib (Primary)
Indications Anaplastic astrocytoma; Astrocytoma; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

13 Jan 2023 Status changed from active, no longer recruiting to completed.
17 Jun 2022 According to a Kazia Therapeutics media release, final data from this study is expected to be submitted for publication by the end of CY2022.
22 Mar 2022 Planned End Date changed from 1 Jun 2024 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com